Humming Bird Power, Precision & Agility

Where to find us

Generic placeholder image
About UCB Ventures
  1. UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. We make long term investments in early stage companies in the US and Europe. Our portfolio reflects our investment strategy.
  2. We invest in start-ups developing novel therapeutic modalities, platforms/assets that address novel biology, or innovative digital solutions, in areas adjacent to or even beyond UCB's current therapeutic focus. We are seeking breakthrough innovations in next generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, RNA targeted therapeutics, and patient engagement solutions that significantly improve outcomes.
  3. We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed long term investors, working closely with entrepreneurs to bring out the best in our portfolio companies.

News

ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

28 Jul 2020 — ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family offices.